scholarly journals Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia

2018 ◽  
Vol 47 (8) ◽  
pp. 773-780 ◽  
Author(s):  
Meri Sieviläinen ◽  
Fabricio Passador-Santos ◽  
Rabeia Almahmoudi ◽  
Solomon Christopher ◽  
Maria Siponen ◽  
...  
Keyword(s):  
Immune Checkpoints ◽  
Programmed Death Ligand 1 ◽  
Indoleamine 2,3 Dioxygenase ◽  
Programmed Death ◽  
Mucosal Dysplasia

scholarly journals IMMUNE CHECKPOINTS INDOLEAMINE 2,3-DIOXYGENASE 1 AND PROGRAMMED DEATH-LIGAND 1 IN ORAL MUCOSAL DYSPLASIA

2019 ◽  
Vol 128 (1) ◽  
pp. e25
Author(s):  
Ms. Meri SievilÄinen ◽  
Dr. Fabricio Passador-Santos ◽  
Ms. Rabeia Almahmoudi ◽  
Mr. Solomon Christopher ◽  
Dr. Maria Siponen ◽  
...  
Keyword(s):  
Immune Checkpoints ◽  
Programmed Death Ligand 1 ◽  
Indoleamine 2,3 Dioxygenase ◽  
Programmed Death ◽  
Mucosal Dysplasia

scholarly journals TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme—Future Perspectives

2020 ◽  
Vol 21 (9) ◽  
pp. 3114 ◽  
Author(s):  
Jakub Litak ◽  
Cezary Grochowski ◽  
Joanna Litak ◽  
Ida Osuchowska ◽  
Krzysztof Gosik ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Immune Checkpoints ◽  
Toll Like Receptor ◽  
Future Perspectives ◽  
Programmed Death Ligand 1 ◽  
Incurable Disease ◽  
Programmed Death ◽  
Strong Relation ◽  
The Central Nervous System

Toll-like-receptor (TLR) family members were detected in the central nervous system (CNS). TLR occurrence was noticed and widely described in glioblastomamultiforme (GBM) cells. After ligand attachment, TLR-4 reorients domains and dimerizes, activates an intracellular cascade, and promotes further cytoplasmatic signaling. There is evidence pointing at a strong relation between TLR-4 signaling and micro ribonucleic acid (miRNA) expression. The TLR-4/miRNA interplay changes typical signaling and encourages them to be a target for modern immunotherapy. TLR-4 agonists initiate signaling and promote programmed death ligand-1 (PD-1L) expression. Most of those molecules are intensively expressed in the GBM microenvironment, resulting in the autocrine induction of regional immunosuppression. Another potential target for immunotreatment is connected with limited TLR-4 signaling that promotes Wnt/DKK-3/claudine-5 signaling, resulting in a limitation of GBM invasiveness. Interestingly, TLR-4 expression results in bordering proliferative trends in cancer stem cells (CSC) and GBM. All of these potential targets could bring new hope for patients suffering from this incurable disease. Clinical trials concerning TLR-4 signaling inhibition/promotion in many cancers are recruiting patients. There is still a lot to do in the field of GBM immunotherapy.

scholarly journals Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer

2017 ◽  
Vol 142 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Esmeralda Celia Marginean ◽  
Barbara Melosky
Keyword(s):  
Colorectal Cancer ◽  
Immune Response ◽  
Microsatellite Instability ◽  
Therapeutic Potential ◽  
Checkpoint Inhibitors ◽  
Death Receptor ◽  
Immune Checkpoints ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

Context.— The world of oncology has changed dramatically in the past few years with the introduction of checkpoint inhibitors and immunotherapy. The promising findings of a small, phase 2 clinical trial that led to the US Food and Drug Administration breakthrough designation and approval of the anti–programmed death receptor-1 (PD-1) drug pembrolizumab (Keytruda, Merck, Kenilworth, New Jersey) to treat metastatic/refractory microsatellite instability–high colorectal cancer (CRC) has significantly boosted interest in immunomodulatory therapies in microsatellite instability–high CRC. Objectives.— To review the immune response to cancer and the role of immune checkpoints, focusing on the technical and interpretation challenges of PD-1/programmed death ligand-1 (PD-L1) testing by pathologists and the clinical implications of the test and the therapeutic potential of treating CRC with checkpoint inhibitors. Data Sources.— A PubMed review was performed of articles pertaining to CRC, microsatellite instability and mismatch repair systems, molecular classification, immune response, PD-1/PD-L1, and immunotherapy. Conclusions.— Exciting success with anti–PD-1/PD-L1 and anticytotoxic T-lymphocyte–associated protein 4 (CTLA4) checkpoint inhibitors has already been reported in melanoma and in lung and renal carcinomas. Recently, microsatellite instability–high CRCs, expressing PD-L1 by immunohistochemistry, regardless of the level of that PD-L1 expression, appeared to respond to checkpoint blockades with anti–PD-1 or anti–PD-L1 agents, whereas microsatellite-stable tumors were much less responsive. With microsatellite instability routinely tested by most centers, studies that include larger cohorts are required to study the predictive role of PD-1/PD-L1 expression in microsatellite instability–high CRC, to assess which immunohistochemistry antibodies to use, to refine the scoring criteria, and to critically analyze the interpretation pitfalls.

scholarly journals Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 212 ◽  
Author(s):  
Maria Tampaki ◽  
Evangelos Ionas ◽  
Emilia Hadziyannis ◽  
Melanie Deutsch ◽  
Katerina Malagari ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Immunity ◽  
Transarterial Chemoembolization ◽  
Univariate Analysis ◽  
Post Treatment ◽  
Immune Checkpoints ◽  
Programmed Death Ligand 1 ◽  
Advanced Hcc ◽  
Programmed Death ◽  
Domain 3

Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization.

scholarly journals VEGF-A and PD-L1 Immunoexpression Association with Meningioma Histopathology Grade

2019 ◽  
Vol 7 (3) ◽  
Author(s):  
Yunnica Yunnica ◽  
Afiati Afiati ◽  
Hermin Aminah Usman ◽  
Bethy Surjawathy Hernowo
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Immune Checkpoints ◽  
Vascular Endothelial ◽  
Chi Square ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Chi Square Test ◽  
Endothelial Growth Factor

Histopathology grade of meningioma is one of the most common factors determining the prognosis and affects the risk of recurrence and aggressiveness of the tumor. Biological factors related to histopathological grade are vascular endothelial growth factor A (VEGF-A) and programmed death-ligand 1 (PD-L1). This research aimed to understand the association between VEGF-A and PD-L1 with meningioma histopathology grade. This is in vivo research on 60 paraffin blocks of meningioma cases at Dr. Hasan Sadikin General Hospital Bandung from April to November 2018. Paraffin block samples consist of grade I (30), grade II (15), and grade III (15) meningioma. Immunohistochemical staining of VEGF-A and PD-L1 performed to all samples. Data analyzed using the chi-square test with SPSS version 24.0 for Windows. The result shows a significant association between VEGF-A and PD-L1 immunoexpression with meningioma histopathology grade. PD-L1 is the most potent factor that influenced the histopathology grade of meningioma. The study concluded that the histopathology grade of meningiomas influenced by angiogenesis and immune checkpoints. VEGF-A and PD-L1 immunoexpression in meningioma considered as a factor that influences the aggressiveness of meningioma. HUBUNGAN IMUNOEKSPRESI VEGF-A DAN PD-L1 DENGAN DERAJAT HISTOPATOLOGI MENINGIOMADerajat histopatologi meningioma merupakan salah satu faktor yang paling umum menentukan prognosis serta memengaruhi risiko rekurensi dan agresivitas tumor. Faktor biologi yang berhubungan dengan derajat histopatologi adalah vascular endothelial growth factor A (VEGF-A) dan programmed death-ligand 1 (PD-L1). Penelitian ini bertujuan mengetahui hubungan imunoekspresi VEGF-A dan PD-L1 dengan derajat histopatologi meningioma. Penelitian in vivo dilakukan pada 60 blok parafin kasus meningioma di Departemen Patologi Anatomi RSUP Dr. Hasan Sadikin Bandung dari April hingga November 2018. Sampel blok parafin terdiri atas meningioma derajat I (30), derajat II (15), dan derajat III (15). Pulasan imunohistokimia VEGF-A dan PD-L1 dilakukan terhadap semua sampel. Data dianalisis menggunakan uji chi-square dengam SPSS versi 24.0 untuk Windows. Hasil penelitian menunjukkan bahwa terdapat hubungan yang signifikan antara VEGF-A dan PD-L1 dengan derajat histopatologi meningioma. PD-L1 merupakan faktor paling kuat yang memengaruhi derajat histopatologi meningioma. Simpulan penelitian ini adalah derajat histopatologi meningioma dipengaruhi oleh faktor angiogenesis dan immune check point. Imunoekspresi VEGF-A dan PD-L1 pada meningioma dapat dipertimbangkan sebagai faktor yang memengaruhi agresivitas meningioma.

Sign in / Sign up

Export Citation Format

Share Document